Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 31, 1997

View Archived Issues

Serine protease inhibitors reported by Akzo Nobel

Astra investigates H. pylori vaccines

Takeda researches follow-up compounds to leuprorelin

New MMP inhibitors reported by Warner-Lambert

New NNRTI described for combination therapy

New anticoagulant drug candidates from Berlex

DuPont Merck reports new fibrinogen antagonists

CP-0840: Dual-action bradykinin antagonist/mu-opioid agonist from Cortech

Shaman describes antidiabetic agents from natural source

Novel antiinfective agents from Tanabe

Potent antitumor agents from Takeda

U.K. biotechnology company offers late-stage vaccine for licensing

NCI discloses anti-HIV agent with novel mechanism of action

Abbott develops protease inhibitor for combination therapy

Cel-Sci presents results with heteroconjugate technology for HIV vaccine development

Genotypic analysis of patients treated with adefovir dipivoxil

Micrologix receives broad patent coverage for peptide antibiotic production method

Preclinical results support Pharmadigm's DHEA development program

Sequus and Protein Sciences collaborate on production and development of HIV Rx

New use reported for a known veterinary anticoccidial agent

Biotech launches Diab II

Sepracor granted U.S. patent for Claritin metabolite

FDA approves antidiabetic drug within 6 months of filing

Iceland moss component displays anti-H. pylori activity in vitro

Teva generic approved

Novel formulation of aciclovir enters pivotal trials

FDA approves Teva drug

SKB acellular DTP vaccine approved in U.S.

Chiron/Baxter collaboration for novel cell therapy product for leukemia

Zeneca/Pharmacopeia collaboration signed

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...